^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CXCL1 (Chemokine (C-X-C motif) ligand 1)

    i
    Other names: CXCL1, FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3, SCYB1, Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)
    Associations

    News

    Trials
    5d
    IL-17F mirrors IL-17 a in dermal fibroblasts and synergizes with TNF to drive inflammation in Th17 inflammatory skin diseases. (PubMed, Cytokine)
    These findings challenge the paradigm of IL-17F as a redundant homolog, demonstrating that within a TNF-rich pro-inflammatory environment, IL-17F overcomes its limited basal potency to mirror the inflammatory drive of IL-17 A functionally. This mechanism provides a biological rationale for the superior clinical efficacy observed with dual IL-17 A/F inhibition in chronic inflammatory skin diseases.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL17A (Interleukin 17A) • MMP1 (Matrix metallopeptidase 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    7d
    Endogenous promoter G-quadruplexes scaffold apurinic/apyrimidinic endonuclease (APE1) to drive gene expression. (PubMed, Nucleic Acids Res)
    Disruption of the G4-APE1 interaction, either genetically or pharmacologically, suppresses gene expression and impairs tumor cell malignant traits. Our findings establish a direct genetic link and mechanistic basis for promoter G4s as crucial drivers of oncogene expression and tumor progression.
    Journal
    |
    CXCL1 (Chemokine (C-X-C motif) ligand 1)
    7d
    MLK4 orchestrates macrophage-induced triple-negative breast cancer invasion and ECM remodeling via enhanced paracrine signaling and NF-κB-MMP axis activation. (PubMed, Cell Death Dis)
    Summarizing, our findings uncover a paracrine signaling involving CXCL1 and MLK4-NF-κB-MMPs axis, which mediates the interactions between TAMs and TNBC cells, enhancing proliferation, mesenchymal transition, ECM remodeling and cancer invasion. This work elucidates a new mechanism of macrophage-induced tumor progression and highlights MLK4 as a promising therapeutic target for disrupting cancer cells-macrophage reciprocal communication in TNBC.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    8d
    ETV7 promotes 5-FU resistance and malignant progression through CXCL1-induced NETs formation in colorectal cancer. (PubMed, Commun Biol)
    Resistance to 5-fluorouracil (5-FU) remains a major challenge in the treatment of colorectal cancer (CRC)...Pharmacological inhibition of CXCL1 or degradation of NETs effectively attenuates ETV7-driven malignant phenotypes in vitro and in vivo. Collectively, these findings establish an ETV7-CXCL1-NETs axis that contributes to 5-FU resistance in CRC and suggest that targeting this pathway may improve chemotherapy response.
    Journal
    |
    CXCL1 (Chemokine (C-X-C motif) ligand 1) • TCF7 (Transcription Factor 7)
    |
    5-fluorouracil
    12d
    The Significance of CXCL1 in Cancer: An Overview of Molecular Mechanisms. (PubMed, Int J Mol Sci)
    It also describes the significance of CXCL1 in cancer-associated diseases such as cancer cachexia, cancer-associated immunodeficiency, neuroinflammatory-mediated affective-like behaviors, bone cancer pain, and acute kidney injury. We also present the effects of obesity on CXCL1-related cancer processes.
    Review • Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    14d
    Sex differences in chemotherapy-induced neuropathic pain: mechanisms and pharmacotherapy. (PubMed, J Pharm Pharmacol)
    Sex is a crucial biological variable in CIPN, influencing drug efficacy through sex-specific neuroimmune mechanisms and hormonal regulation. These findings underscore the necessity of incorporating sex as a key variable in analgesic development and clinical practice to achieve personalized pain management in CIPN patients.
    Review • Journal
    |
    TLR9 (Toll Like Receptor 9) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • S1PR1 (Sphingosine-1-Phosphate Receptor 1)
    15d
    Decoding the role of CXC chemokines in pulmonary metastasis of colorectal cancer using integrative computational approaches. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    In silico immune simulations predicted robust humoral and cellular immune responses with the establishment of immunological memory. This integrative bioinformatics and immunoinformatics study identifies immune-associated CXC chemokines as promising prognostic biomarkers in CRC pulmonary metastasis and proposes a rationally designed multi-epitope vaccine candidate for further experimental validation and potential preclinical development in CRC immunotherapy.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • TLR4 (Toll Like Receptor 4) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • CXCL3 (C-X-C Motif Chemokine Ligand 3) • TLR2 (Toll Like Receptor 2)
    15d
    Development of a novel immune infiltration-based gene signature to predict prognosis and immunotherapy response of a novel anti-PD-L1/TGF-β bifunctional fusion protein in recurrent cervical cancer. (PubMed, Hum Vaccin Immunother)
    Anti-PD-L1 and TGF-β bifunctional fusion proteins are feasible and effective for recurrent cervical cancer through the IL 17 signaling pathway and TGF-β signaling pathways. A novel immune infiltration-based gene signature consisting of PMEPA1, FSTL3, SERPINE1, CXCL1, CXCL8, JUND, and MAP2K2 plays a crucial role in recurrent cervical cancer patients with anti-PD-L1 and TGF-β bifunctional fusion proteins.
    Journal • Gene Signature • PD(L)-1 Biomarker • IO biomarker
    |
    MAP2K2 (Mitogen-activated protein kinase kinase 2) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • TGFB1 (Transforming Growth Factor Beta 1) • IL17A (Interleukin 17A) • SERPINE1 (Serpin Family E Member 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    20d
    In Silico Transcriptomic Analysis for Identification of Potential Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Cervical Cancer using a Hybrid Genetic Algorithm-Support Vector Machine Approach. (PubMed, Arch Iran Med)
    The identified gene signatures may serve as candidates for hypothesis generation and provide a computational framework to prioritize biomarkers and therapeutic targets in cervical cancer. However, these findings are based on in silico analyses and require experimental and clinical validation before translation into practice.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • DNMT1 (DNA methyltransferase 1) • AURKB (Aurora Kinase B) • PCNA (Proliferating cell nuclear antigen) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • TP63 (Tumor protein 63) • CDK1 (Cyclin-dependent kinase 1) • MMP1 (Matrix metallopeptidase 1) • MYBL2 (MYB Proto-Oncogene Like 2) • ZEB2 (Zinc Finger E-Box Binding Homeobox 2) • CCNB1 (Cyclin B1) • CTGF (Connective tissue growth factor) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • E2F1 (E2F transcription factor 1) • KPNA2 (Karyopherin Subunit Alpha 2) • SLC5A1 (Solute Carrier Family 5 Member 1)
    22d
    Development and validation of a tumor-derived CXCL1 qPCR assay to support patient selection for anti-CXCL1 therapeutics in bladder cancer. (PubMed, Exp Mol Pathol)
    We present a robust, analytically validated qPCR assay for quantifying CXCL1 expression in FFPE tumor specimens. The assay demonstrated excellent concordance with RNA-seq expression values, supporting its reliability for measuring CXCL1 mRNA expression in bulk tumor specimens and its potential utility as a companion diagnostic in future CXCR-2-CXCL1-targeted clinical trials.
    Journal
    |
    CXCR2 (Chemokine (C-X-C motif) receptor 2) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    28d
    A CD138+ tumor-associated macrophage-Siglec-F+ neutrophil feedforward loop promotes immune evasion in pancreatic cancer. (PubMed, J Clin Invest)
    Targeting CD138+ TAMs by disrupting IL-34-syndecan-1 signaling with anti-IL-34 neutralizing antibodies significantly suppresses PDAC progression, especially when combined with anti-PD-1 antibodies. Together, our study elucidates a CD138+ TAM-Siglec-F+ neutrophil axis that drives immune escape in PDAC and proposes a therapeutic strategy that integrates IL-34-syndecan-1 signaling blockade with anti-PD-1 immunotherapy for the treatment of PDAC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    SDC1 (Syndecan 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    29d
    The Role of Neutrophils in Non-Alcoholic Fatty Liver Disease: Mechanisms and Clinical Significance. (PubMed, J Inflamm Res)
    More crucially, neutrophils have been shown to promote disease progression from simple fatty liver to non-alcoholic steatohepatitis, liver fibrosis, and hepatocellular carcinoma by forming complex interaction networks with macrophages, hepatic stellate cells, and hepatocytes. These findings not only deepen our understanding of the immunopathological mechanisms of NAFLD but also highlight the immense clinical translational potential of neutrophils as novel biomarkers and therapeutic targets.
    Review • Journal
    |
    CXCR2 (Chemokine (C-X-C motif) receptor 2) • CXCL1 (Chemokine (C-X-C motif) ligand 1)